A Phase 2 clinical trial studying CagriSema, which includes cagrilintide, reached completed status as of September 10, 2026. The study, registered as NCT06797869, was titled "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy." It compared CagriSema to placebo in participants with type 2 diabetes and painful diabetic peripheral neuropathy.
The trial was conducted at the Phase 2 stage of clinical development. Its completion status means the study has concluded according to its registered protocol, though this update does not include any reported results or outcome data. Cagrilintide remains classified as an unapproved compound under research investigation and is not approved for any therapeutic use.
This brief reflects only the status update recorded in the trial registry entry. No efficacy, safety, or comparative outcome information is included in this event record. Readers interested in the study design, phase, or population criteria can consult the referenced clinical trial listing directly. For general background on cagrilintide's research status and development history, readers can refer to the compound overview.